Fieldview Capital Management, LLC Blueprint Medicines Corp Transaction History

Fieldview Capital Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$79.22 - $128.4 $1.8 Million - $2.92 Million	-22,757 Reduced 82.96%	4,673 $599 Million
Q1 2025 May 15, 2025	SELL	$86.69 - $115.63 $1.01 Million - $1.35 Million	-11,659 Reduced 29.83%	27,430 $2.43 Billion
Q4 2024 Feb 14, 2025	BUY	$82.48 - $101.39 $3.22 Million - $3.96 Million	39,089 New	39,089 $3.41 Billion

8.54M

14.8K

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Fieldview Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fieldview Capital Management, LLC with notifications on news.